GlaxoSmithKline (LON:GSK) had its price objective raised by Deutsche Bank from GBX 1,550 ($20.25) to GBX 1,575 ($20.58) in a report issued on Monday morning, Digital Look reports. The firm currently has a hold rating on the stock.
Several other research analysts have also issued reports on GSK. Jefferies Financial Group reiterated a buy rating and issued a C$15.00 price target on shares of Aphria in a report on Friday, May 24th. Liberum Capital reiterated a hold rating on shares of Daily Mail and General Trust P L C in a report on Tuesday, July 2nd. Barclays increased their price objective on Intuit from $225.00 to $237.00 and gave the stock an equal weight rating in a research note on Friday, May 24th. Goldman Sachs Group set a $13.00 price objective on Ford Motor and gave the stock a buy rating in a research note on Thursday, June 13th. Finally, UBS Group downgraded Telstra from a buy rating to a neutral rating in a research note on Monday, July 1st. Two investment analysts have rated the stock with a sell rating, twelve have assigned a hold rating and five have issued a buy rating to the company. The stock presently has an average rating of Hold and an average price target of GBX 1,535.88 ($20.07).
Shares of LON:GSK opened at GBX 1,625.20 ($21.24) on Monday. The business has a 50 day moving average price of GBX 1,583.69. The company has a market capitalization of $81.44 billion and a price-to-earnings ratio of 20.70. The company has a current ratio of 0.72, a quick ratio of 0.45 and a debt-to-equity ratio of 942.07. GlaxoSmithKline has a 52-week low of GBX 1,408.80 ($18.41) and a 52-week high of GBX 1,651 ($21.57).
In other GlaxoSmithKline news, insider Manvinder Singh Banga purchased 458 shares of the firm’s stock in a transaction that occurred on Wednesday, May 1st. The stock was bought at an average cost of GBX 1,568 ($20.49) per share, with a total value of £7,181.44 ($9,383.82). Over the last three months, insiders bought 482 shares of company stock valued at $755,935.
GlaxoSmithKline Company Profile
GlaxoSmithKline plc engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products in the United Kingdom, the United States, and internationally. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare.
Featured Article: Gap Up Stocks
Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.